Work

Responsiveness of Intrinsic Subtypes to Adjuvant Anthracycline Substitution in the NCIC.CTG MA.5 Randomized Trial

Year: 2020

Type: article

Abstract: Recent studies suggest that intrinsic breast cancer subtypes may differ in their responsiveness to specific chemotherapy regimens. We examined this hypothesis on NCIC.CTG MA.5, a clinical trial randomizing premenopausal women with node-positive breast cancer to adjuvant CMF (cyclophosphamide-methotrexate-fluorouracil) versus CEF (cyclophosphamide-epirubicin-fluorouracil) chemotherapy.

Source: Carolina Digital Repository (University of North Carolina at Chapel Hill)

DOI: 10.17615/qq2s-p655

Authors: Parker, Joel S., Perou, Charles M., Levine, Mark N., Leung, Samuel, Voduc, K. David, Davis, Carole, Bernard, Philip S., Ellis, Matthew J., Tu, Dongsheng, Davies, Sherri, Cheang, Maggie C.U., Pritchard, Kathleen I., Shepherd, Lois E., Ebbert, Mark T.W., Jiang, Shan, Stijleman, Inge J., Nielsen, Torsten O., Chia, Stephen K.

Institution: University of North Carolina at Chapel Hill

Language: English

Topic: Breast Cancer Treatment Studies

Subfield: Cancer Research

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: green

Funders: Michael Smith Health Research BC, Terry Fox Foundation, National Cancer Institute

Award: G861276625

OpenAlex ID: W4300263604

FWCI:

Cites:

Cited by:

Related to: 10